Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Tharimmune (NASDAQ:THAR) has been granted a European patent for biodegradable polymeric nanoparticles designed to deliver therapeutic antibodies and peptides. The technology aims to enhance drug delivery by improving stability and reducing systemic side effects, particularly in cancer therapies. The nanoparticles feature tunable size, non-toxic profiles, and extended drug half-life capabilities. A comparable U.S. patent application is under review. The patent complements Tharimmune's existing pipeline, including colonic targeting developed with Intract Pharma. The company is exploring strategic partnerships with antibody conjugation specialists to enhance the platform's targeting capabilities.
Tharimmune (NASDAQ:THAR) ha ricevuto un brevetto europeo per nanoparticelle polimeriche biodegradabili progettate per consegnare anticorpi terapeutici e peptidi. La tecnologia mira a migliorare la somministrazione del farmaco aumentando la stabilità e riducendo gli effetti collaterali sistemici, in particolare nelle terapie per il cancro. Le nanoparticelle presentano dimensioni regolabili, profili non tossici e capacità di prolungare la vita del farmaco. Una domanda di brevetto comparabile negli Stati Uniti è attualmente in fase di revisione. Il brevetto integra il pipeline esistente di Tharimmune, inclusa la somministrazione mirata al colon sviluppata con Intract Pharma. L'azienda sta esplorando partnership strategiche con specialisti nella coniugazione di anticorpi per migliorare le capacità di targeting della piattaforma.
Tharimmune (NASDAQ:THAR) ha sido otorgada una patente europea para nanopartículas poliméricas biodegradables diseñadas para entregar anticuerpos terapéuticos y péptidos. La tecnología tiene como objetivo mejorar la entrega de medicamentos al aumentar la estabilidad y reducir los efectos secundarios sistémicos, especialmente en terapias contra el cáncer. Las nanopartículas cuentan con un tamaño ajustable, perfiles no tóxicos y capacidades de prolongar la vida media del medicamento. Una solicitud de patente comparable en EE.UU. está en revisión. La patente complementa la cartera existente de Tharimmune, que incluye la administración dirigida al colon desarrollada con Intract Pharma. La empresa está explorando asociaciones estratégicas con especialistas en conjugación de anticuerpos para mejorar las capacidades de segmentación de la plataforma.
Tharimmune (NASDAQ:THAR)는 치료 항체와 펩타이드를 전달하도록 설계된 생분해성 고분자 나노입자에 대해 유럽 특허를 취득했습니다. 이 기술은 안정성을 향상시키고 시스템적 부작용을 줄여 특히 암 치료에서 약물 전달을 개선하는 것을 목표로 합니다. 나노입자는 조정 가능한 크기, 비독성 프로필 및 약물 반감기 연장 기능을 갖추고 있습니다. 유사한 미국 특허 출원은 검토 중입니다. 이 특허는 Tharimmune의 기존 파이프라인을 보완하며, 여기에는 Intract Pharma와 함께 개발한 결장 타겟팅이 포함됩니다. 이 회사는 플랫폼의 타겟팅 기능을 향상시키기 위해 항체 결합 전문업체와의 전략적 파트너십을 탐색하고 있습니다.
Tharimmune (NASDAQ:THAR) a obtenu un brevet européen pour des nanoparticules polymériques biodégradables conçues pour délivrer des anticorps thérapeutiques et des peptides. La technologie vise à améliorer la délivrance des médicaments en augmentant la stabilité et en réduisant les effets secondaires systémiques, en particulier dans le cadre des thérapies contre le cancer. Les nanoparticules présentent une taille réglable, des profils non toxiques et la capacité d’allonger la demi-vie des médicaments. Une demande de brevet comparable aux États-Unis est en cours d'examen. Le brevet complète le portefeuille existant de Tharimmune, y compris le ciblage colique développé avec Intract Pharma. L'entreprise explore des partenariats stratégiques avec des spécialistes en conjugaison d'anticorps pour améliorer les capacités de ciblage de la plateforme.
Tharimmune (NASDAQ:THAR) hat ein europäisches Patent für biologisch abbaubare polymerische Nano-Partikel erhalten, die zur gezielten Abgabe von therapeutischen Antikörpern und Peptiden entwickelt wurden. Die Technologie zielt darauf ab, die Arzneimittelabgabe zu verbessern, indem die Stabilität erhöht und systemische Nebenwirkungen reduziert werden, insbesondere bei Krebstherapien. Die Nanopartikel zeichnen sich durch ein einstellbares Größe, ungiftige Profile und die Fähigkeit zur Verlängerung der Wirkstoff-Halbwertszeit aus. Ein vergleichbarer US-Patentantrag befindet sich derzeit in Prüfung. Das Patent ergänzt die bestehende Pipeline von Tharimmune, darunter die gezielte Abgabe im Dickdarm, die in Zusammenarbeit mit Intract Pharma entwickelt wurde. Das Unternehmen erkundet strategische Partnerschaften mit Spezialisten für Antikörperverknüpfungen, um die Zielgerichtetheit der Plattform zu verbessern.
- Secured European patent for innovative drug delivery technology
- Technology addresses key challenges in therapeutic antibody and peptide delivery
- Platform complements existing pipeline and opens potential partnership opportunities
- None.
Insights
The granted European patent significantly strengthens Tharimmune's intellectual property portfolio in the critical area of drug delivery systems. The technology's focus on biodegradable polymeric nanoparticles for targeted therapeutic delivery represents a valuable asset with broad applications, particularly in cancer treatment. The pending US patent application could further enhance the company's IP position in key markets.
The patent's scope covering design, preparation and therapeutic applications provides comprehensive protection for the technology platform. This positions Tharimmune for potential licensing opportunities and strategic partnerships, particularly with companies developing antibody-drug conjugates. The technology's ability to address drug delivery challenges could make it an attractive platform for pharmaceutical companies looking to improve their therapeutic candidates' efficacy.
The nanoparticle delivery platform addresses important challenges in targeted therapeutics by potentially improving drug stability, circulation time and targeted delivery while reducing side effects. This technology could be particularly valuable for antibody and peptide-based drugs that face delivery challenges. The platform's versatility and potential applications in cancer therapy represent a significant market opportunity.
The strategic alignment with Tharimmune's existing colonic targeting programs and partnership with Intract Pharma demonstrates a cohesive development strategy. The company's active pursuit of partnerships in antibody conjugation indicates a clear commercialization pathway. However, investors should note that significant development and validation work may be needed before commercial applications materialize.
BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric nanoparticles created for carrying therapeutic and targeting agents. With particular utility in cancer therapies, this innovative platform is designed to enhance the delivery of therapeutic antibodies and peptides, which are often limited by enzymatic degradation and poor systemic circulation.
The patent covers the design, preparation and therapeutic application of nanoparticles formed from biodegradable block copolymers. These nanoparticles exhibit tunable size, non-toxic profiles and the ability to prolong drug half-life in the bloodstream. By penetrating biological barriers and delivering encapsulated drug directly to disease sites, reduces systemic side effects and toxicity while improving the therapy's effectiveness. An application for a comparable U.S. patent has been submitted to the United States Patent and Trademark Office, and is currently under review.
"Molecularly targeted therapies are effective alternatives to conventional treatments, but challenges remain in delivering these antibody-based and peptide drugs. We believe our system represents a novel solution, addressing critical challenges with stability and absorption," said Randy Milby, Chief Executive Officer of Tharimmune. "We believe the platform can become an important component of future therapies, and receipt of this European patent marks an exciting first step."
This new patent complements Tharimmune's existing pipeline, including colonic targeting developed through the Company's partnership with Intract Pharma. While Tharimmune initially focused on tablet-based solutions for lower gastrointestinal delivery, this new intellectual property represents a potential platform to complement its growing pipeline. Tharimmune is also actively exploring strategic partnerships with companies that specialize in antibody conjugation to further enhance the targeting capabilities of its platform.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology and inflammation. The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding Tharimmune's or Intract's future financial or operating performance, the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's and Intract's expectations with respect to the Merger, including the timing of entering into a definitive agreement, the timing of closing thereof, the pro forma ownership of the combined company, anticipated financing plans, the combined company's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, Tharimmune and Intract's management. Tharimmune may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023 and other periodic reports filed by Tharimmune from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Tharimmune's and Intract's views as of the date of this release. Subsequent events and developments may cause Tharimmune's views to change; however, Tharimmune does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing Tharimmune's views as of any date subsequent to the date of this release.
Contacts:
Tharimmune, Inc.
ir@tharimmune.com
Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on accesswire.com
FAQ
What patent did Tharimmune (THAR) receive in November 2023?
What is the main purpose of Tharimmune's (THAR) new patented technology?
Is Tharimmune (THAR) seeking patent protection in the United States?
